Sulis Therapeutics ApS: Financial statements 2025
CVR: 44445832
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Sulis Therapeutics ApS (CVR 44445832) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR -866,109 and a net result of EUR -892,687 compared with EUR -202,314 the year before. Equity in the 2025 report amounted to EUR -938,524. The company had 1 employee in the financial year.
- Gross Profit
- EUR -866,109
- Profit/Loss
- EUR -892,687
- Equity
- EUR -938,524
- Total Assets
- EUR 1,504,573
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -866K EUR | -893K EUR | -939K EUR | 1 |
| 2024 | - | -167K EUR | -202K EUR | -46K EUR | 1 |
Official annual report
How creditworthy is Sulis Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of August 5, 2025, Claus Elsborg Olesen has joined the board of directors of Sulis Therapeutics ApS.
As of August 5, 2025, Martin Roelsgaard Jakobsen has joined the board of directors of Sulis Therapeutics ApS.
Sulis Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -167,138, and the net result was DKK -202,314.
About Sulis Therapeutics ApS
Sulis Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Selskabet af 21. november 2023 ApS. The management consists of Claus Elsborg Olesen. The board consists of Sten Verland (chair), Claus Elsborg Olesen and Martin Roelsgaard Jakobsen. The company is owned by CLAUS OLESEN HOLDING ApS, MR Jakobsen Holding ApS and Shinka Life Sciences AB. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR -866,109 and a net result of EUR -892,687 compared with EUR -202,314 the year before. Equity in the 2025 report amounted to EUR -938,524.